Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 80 years old and have been diagnosed with chronic hypersensitivity pneumonitis, a lung disease linked to a connective tissue condition (such as rheumatoid arthritis, systemic sclerosis, or mixed connective tissue disease), or an unclassified interstitial lung disease (ILD).
- You are about to start treatment with certain medications (mycophenolate mofetil, mycophenolate sodium, and/or prednisone) for your lung condition.
- A recent CT scan of your lungs (taken within the last year) shows signs of scarring or fibrosis.
- Your breathing test results show your lungs are working at or above certain minimum levels (confirm with trial site for exact values).
Who may not be able to join:
- You have ever taken or are currently taking any FDA-approved anti-fibrotic (anti-scarring) medication for lung disease.
- Your CT scan shows more emphysema (lung damage from air trapping) than scarring/fibrosis.
- You are pregnant, trying to become pregnant, or plan to become pregnant during the study.
- You have a reason why you cannot have an MRI scan.
- You have a reason why you cannot receive a certain type of MRI dye (gadolinium-based contrast agent).
- You have had a significant amount of research-related radiation exposure in the past year (confirm with trial site).
- You have a history of chronic kidney disease with poor kidney function below a certain level (confirm with trial site).
- You are being treated with medication for significant high blood pressure in the lungs (pulmonary hypertension).
- You have had a respiratory infection in the past 6 weeks.
- You have smoked anything in the past 6 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sydney Montesi, MD, Massachusetts General Hospital
Phone: 617 724 4030
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in SUVmax25 over the entire lungs; Change in the rate of contrast washin (kwashin) over the entire lungs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.